Share Name Share Symbol Market Type Share ISIN Share Description
Puretech Health LSE:PRTC London Ordinary Share GB00BY2Z0H74 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00p -1.47% 134.00p 134.00p 139.00p 136.00p 135.00p 136.00p 41,521 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 3.6 -67.4 -17.0 - 318.10

Puretech (PRTC) Latest News

More Puretech News
Puretech Takeover Rumours

Puretech (PRTC) Share Charts

1 Year Puretech Chart

1 Year Puretech Chart

1 Month Puretech Chart

1 Month Puretech Chart

Intraday Puretech Chart

Intraday Puretech Chart

Puretech (PRTC) Discussions and Chat

Puretech Forums and Chat

Date Time Title Posts
25/7/201716:51PureTech Health - innovative healthcare100

Add a New Thread

Puretech (PRTC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-08-18 15:35:07134.0010,00013,400.00UT
2017-08-18 14:34:46135.00382515.70AT
2017-08-18 10:33:59134.453,7195,000.29O
2017-08-18 09:56:32135.001,5682,116.80AT
2017-08-18 09:56:32135.001,4972,020.95AT
View all Puretech trades in real-time

Puretech (PRTC) Top Chat Posts

DateSubject
18/8/2017
09:20
Puretech Daily Update: Puretech Health is listed in the General Financial sector of the London Stock Exchange with ticker PRTC. The last closing price for Puretech was 136p.
Puretech Health has a 4 week average price of 122p and a 12 week average price of 115p.
The 1 year high share price is 170p while the 1 year low share price is currently 110p.
There are currently 237,387,951 shares in issue and the average daily traded volume is 23,012 shares. The market capitalisation of Puretech Health is £318,099,854.34.
12/7/2017
12:43
rambutan2: Getting there: PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Gelesis, Inc. (a subsidiary of PureTech Health) has completed treatment of the final patient in the pivotal GLOW (Gelesis Loss Of Weight) Study. GLOW was designed to assess the long-term efficacy and safety of lead product candidate Gelesis100 over a six-month period across a broad patient population. Results from this registration-enabling trial are anticipated in Q3 2017. Gelesis has also enrolled its first European patient in the ongoing LIGHT-UP study with its second product candidate, Gelesis200, for weight loss and glycaemic control. LIGHT-UP will enrol individuals across the United States, Canada, and Europe who are overweight or have obesity and also have prediabetes or metformin-treated type 2 diabetes. Dr. Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, said: "We're delighted to have achieved these important milestones and to expand the breadth of the Gelesis platform. As a result of new, preclinical research and the pioneering work of Gelesis in this emerging field of mechanobiology, we are also planning or initiating pilot studies across a number of additional indications including early nonalcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), and other gastrointestinal disorders." http://uk.advfn.com/stock-market/london/puretech-PRTC/share-news/PureTech-Health-PLC-PRTCs-Gelesis-Notes-Last-Patie/75218542
05/7/2017
16:40
lendmeafiver: That was some jump in share price on zero newsflow, back to the IPO price by the end of the week?!
29/6/2017
15:02
lendmeafiver: Share price has ticked up ever so slightly also, not sure if it's anything to do with that news or Chowrira's continuous buying of stock or a combination of them both.
29/6/2017
11:41
rambutan2: BOSTON and SAN FRANCISCO, June 28, 2017 - Akili Interactive Labs, Inc. ("Akili") today announced the appointment of former Cubist Pharmaceuticals CEO, Robert J. Perez, as Executive Chairman. Mr. Perez has been a commercial advisor with the company for the past year and will now be joining in the more official leadership role as the company continues its growth. Additionally, the company has added former DreamWorks Interactive CEO, Glenn Entis, and former Chief Game Designer at Google, Noah Falstein, as Executive Advisors. These three biotech and game industry veterans will bring their cross-disciplinary expertise to the Akili team as the company advances its diverse product portfolio and prepares for the potential commercialization of Akili's lead product, Project:EVO(TM) . The Project:EVO(TM) platform is currently being evaluated in a pivotal, registration-enabling trial in patients with paediatric ADHD, which is expected to read out in the second half of 2017. http://uk.advfn.com/stock-market/london/puretech-PRTC/share-news/PureTech-Health-PLC-PRTCs-Akili-Names-Former-Cubis/75130350
21/5/2017
18:10
rambutan2: Karuna is progressing a potential blockbuster: http://uk.advfn.com/stock-market/london/puretech-PRTC/share-news/PureTech-Health-PLC-PureTechs-Karuna-to-Present-at/74647047
03/5/2017
15:56
lendmeafiver: Good Gelesis news, in my view that product covers the current share price on its own!
06/4/2017
10:13
lendmeafiver: Further good news today, the likes of Numis raising its price target to 246p earlier in the week, current share price is far too cheap in relation to the advanced stage of some of its investments in my view.
04/1/2017
21:41
lendmeafiver: the current share price is a great opportunity to invest at circa 30% less than the ipo price, I think the tide is turning here
04/1/2017
12:57
lendmeafiver: Certainly improved interest and share price here since the New Year, perhaps driven by the Sunday Times but also been some good brokers reports out fairly recently.
Puretech share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20170819 03:34:12